
|Articles|December 20, 2013
Study Compares Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients
A study published by the American Journal of Pharmacy Benefits compares dose escalation patterns of patients treated with TNF blockers.
Advertisement
A new study comparing the dose escalation patterns of rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab found that etanercept users were significantly less likely to have a dose escalation. The study, published by the American Journal of Pharmacy Benefits, notes that dose escalation is associated with higher drug treatment costs and greater risk of adverse events.
To read this American Journal of Pharmacy Benefits study in its entirety, follow
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Workforce Preparation for Fall Immunization Season Starts Now
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5






































































































